Varonis Systems, Inc. (VRNS) Stock Price & How to Invest

Varonis Systems is a data-security software company focused on protecting an organization's most sensitive asset: its data. Where most cybersecurity tools guard the network perimeter or endpoints, Varonis monitors the data itself, mapping where sensitive files live, who can access them, how access is used, and flagging risky or anomalous behavior across cloud and on-premises stores (Microsoft 365, Salesforce, AWS, Google Workspace, and more). Its platform handles data security posture management, data access governance, and threat detection, helping companies find overexposed data, lock down permissions, and detect insider threats or ransomware early. Varonis sells to enterprises in regulated industries (finance, healthcare, government) that face strict data-protection rules. The company has moved from selling perpetual licenses to a software-as-a-service subscription model, and pushes a managed data detection and response (MDDR) service. Founded in 2005 and headquartered in New York, Varonis competes in the fast-growing data-centric security niche.

On October 15, 2026, Varonis signed a definitive agreement to be acquired by Proofpoint, the email and human-risk security company owned by private equity firm Thoma Bravo, in an all-cash deal at $49.75 per share, valued at approximately $6.3 billion. The Varonis board approved it unanimously. The price is a 52% premium to the $32.71 close on June 22, 2026, the last full trading day before sale rumors first surfaced, and a 17% premium to the $42.35 close on September 1, 2026, before further media reports. Thoma Bravo is providing committed equity financing and has secured debt commitments, and Ontario Teachers' Pension Plan agreed to invest in Proofpoint alongside the deal. Closing is expected in the first half of 2027, subject to Varonis shareholder approval at a special meeting, regulatory approvals and customary conditions. When it closes, Varonis will become private and its shares will stop trading on Nasdaq.

The business going into the deal was growing at a steady clip: trailing twelve-month revenue reached ~$688 million, up ~18% year over year in Q2 2026, with ~$139 million of free cash flow but a GAAP net loss of ~$141 million. As of October 16, 2026 the shares closed at $48.70, up ~52% year to date (most of it on the takeover reports) and down ~19% over one year, and at least eight brokers downgraded the stock to neutral or hold on October 16 with price targets set at the $49.75 deal price.

The central risk is deal failure. The merger needs Varonis shareholder approval and regulatory clearance, and a transaction expected to close in the first half of 2027 leaves months for financing markets, antitrust review or business conditions to change. If it broke, the stock would likely return toward a level set by fundamentals; the last undisturbed close cited in the deal release was $32.71 on June 22, 2026, well below the $49.75 offer, although that figure is history rather than a forecast. Holders who buy at $48.70 cap their gain at roughly 2% plus nothing in dividends, since Varonis pays none, and give up any upside a standalone Varonis might have earned. The underlying business still carries the earlier risks while it waits: GAAP losses (~$141 million trailing), heavy stock-based compensation and competition from Microsoft, Palo Alto Networks, CrowdStrike and focused DSPM rivals. Walnut is not an investment adviser; this describes the situation rather than recommending a course of action.

19 analysts publish price targets on VRNS, averaging $51.76 against a $48.72 price as of October 2026, or +6.2%. The published targets run from $45.00 to $58.00, a narrow spread, and the ratings split 10 buy, 12 hold, 0 sell. Over the last six months there have been 4 raises and 8 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VRNS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Varonis Systems, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The deal price now sets the stock price. With a signed definitive agreement at $49.75 in cash, VRNS trades as a merger-arbitrage position. The most optimistic published target, $58.00, assumes this works close to its best case.

The case against. The central risk is deal failure. The most pessimistic target, $45.00, is roughly what VRNS is worth if this bites instead.

Read the full bull and bear case on VRNS, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Varonis Systems, Inc. (VRNS) has had one share split in the last 10 years:

• 3:1 on March 15, 2021, so every share held became 3 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of VRNS the day before the 3:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Varonis Systems, Inc.'s investor relations page or your broker.

• Deal price: $49.75 per share in cash (Proofpoint / Thoma Bravo)
• Transaction value: ~$6.3 billion; ~8.4x LTM revenue per the deal release
• Expected close: First half of 2027
• Share price: ~$48.70 (Oct 16, 2026), ~2% below the offer
• Revenue (TTM): ~$688 million, up ~18% year over year in Q2 2026
• Free cash flow (TTM): ~$139 million
• Net income (TTM): ~-$141 million GAAP
• Market cap: ~$5.6 billion

VRNS is no longer valued on ARR growth or price to sales. The cash offer of $49.75 caps the share price, and the gap to the October 16 close reflects the time until a first-half 2027 close and the risk of the deal failing. The offer priced Varonis at about 8.4 times trailing revenue and 53 times trailing free cash flow, according to the joint press release.

If you want VRNS exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to VRNS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VRNS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BUG, IHAK), which spreads the position across many companies. Or build it into a focused thematic portfolio, so VRNS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VRNS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Varonis (VRNS) is now a pending cash takeover rather than an ARR-growth story. Holders are set to receive $49.75 per share if Proofpoint's deal closes in the first half of 2027, so the remaining upside is the roughly 2% gap between the October 16 close of $48.70 and the offer price, and the main risk is that shareholder or regulatory approval fails and the stock falls back to trading on its own fundamentals.

Whether VRNS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VRNS a buy or a sell?, and where the stock could go from here in the VRNS stock forecast.

For income investors, whether VRNS pays a dividend and how the payout looks is covered in does VRNS pay a dividend? And to weigh VRNS against a peer, read the full side-by-side comparisons: VRNS vs MSFT and VRNS vs PANW.